Copyright © 1986 by the European Society of Cardiology.
© 1986 The European Society of Cardiology
Randomized placebo-controlled comparative study of nifedipine, verapamil and isosorbide dinitrate in the treatment of angina at rest
*Cattedra di Cardiologia, Università degli Studi Bari, Italy
Fondazione Clinica del Lavoro, Istituto di Ricovero e Cura a Carattere Scientifico, Centro Medico di Riabilitazione di Cassano Murge, Divisione di Cardiologia Cassano Murge, Bari, Italy
Received 17 May 1985; revised 7 August 1985; .
Prof Paolo Rizzon, Cattedra di Cardiologia, Ospedale Consorziale, Policlinico, Pizza Giulio Cesare, 70124 Bari-Italy
Abstract
Twenty-nine patients with angina at rest took part in a randomized placebo-controlled short-term study to assess the relative effectiveness of different dosages of nifedipine (N), verapamil (V) and isosorbide dinitrate (ISDN) versus placebo and to evaluate the antianginal effects of a sustained-release preparation of ISDN (sr), of N retard form (r) and of V retard form (r).
The 29 patients were divided into 3 groups: the first group of patients (10 patients, group A) was treated with N10 mg six times daily, V 80 mg three times daily and ISDN 10 mg six times daily; the second group of patients (9 patients, group B) was treated with N 20 mg six times daily, V 120 mg four times daily and ISDN 20 mg six times daily; the third group of patients (10 patients, group C) was treated with N r 20 mg four times daily, V r 120 mg three times daily and ISDN sr 40 mg four times daily.
The daily frequency of ischaemic episodes (IE) was assessed by Holter monitoring. The effect of each drug on the mean frequency of IE was compared with the placebo using a one-way analysis of variance and the Newman-Keuls test.
In group A, the mean daily frequency of IE per patient was 8.1 ± 5.9 with the placebo, 1.4 ± 1.9 with N (P>0.001; –82%), 4 ± 3.6 with V (P: NS; –50%) and 4.3 ± 3.6 with ISDN (P: NS; –46%). In group B it was 6.4 ± 3.4 with the placebo, 0.5 ± 1.6 with N (P>0.01; –91%), 0.3 ± 0.5 with V (P>0.01; –95%) and 1.2 ± 1 with ISDN (P>0.01; –82%). In group C it was 10.3 ± 8.7 with the placebo, 0.7 ± 1.6 with N r (P>0.01; –93%), 1 ± 2.5 with V r (P>0.01; –90%) and 5.1 ± 7.7 with ISDN sr (P: NS; –50%).
In group A a reduction of 100% in the number of recorded IES was achieved in 5/10 patients by using N, in none by V, and in 1/10 by ISDN. In group B, in 8/9 patients by N, in 6/9 by V and in 3/9 by ISDN. In group C, in 8/10 patients by both N r and V r in 4/10 patients by ISDN sr.
It is concluded that calcium antagonist drugs at adequate dosages are substantially more effective than ISDN in relieving angina at rest and thus they may be considered as first choice therapy in the management of angina at rest. Furthermore, long-acting preparations of both nifedipine and verapamil were comparably effective in reducing the frequency of IE whereas isosorbide dinitrate, in the sustained release form, was again less effective.
Key Words: Angina at rest • Holter monitoring • antianginal drugs